Name: Cecile Guegan
New title: Chief financial officer and executive vice president
Previous title: Interim chief financial officer
Cecile Guegan has been named Pfizer’s permanent chief financial officer, becoming the large pharma’s first-ever woman to hold that position in the C-suite. Guegan is a Pfizer veteran who has worked her way up the ranks for over two decades in numerous financial roles.
“Her more than 25 years of experience paired with her strategic vision will provide the financial rigor and focus this next chapter demands as we aim for meaningful growth,” CEO Albert Bourla said in a statement.
Guegan took over as Pfizer’s interim CFO a few months ago, after Dave Denton left the company to join Nike.
The change comes as Pfizer stages a comeback following its post-pandemic slump. Pfizer sang a positive tune in its third quarter earnings report this month, raising its 2026 revenue guidance from $62 billion to $64 billion. Its better-than-expected performance was driven by a 25% operational revenue bump for its blood thinner medication Eliquis and a 33% global revenue increase for its oncology antibody-drug conjugate Padcev.
After its earnings report, analysts noted that with its COVID-era growth story in the rearview mirror, the next major question hanging over the company is how it will navigate patent losses in the next few years for several key blockbusters, including Eliquis, and its cancer drugs Ibrance and Xtandi.
The pressure is on Pfizer to deliver on its dealmaking and pipeline bets. In particular, Pfizer has developed a deep roster of clinical hopefuls in obesity — including the candidates it brought into the fold after its $10 billion acquisition of Metsera.
“With significant LOEs in the mid-term, growth depends heavily on the pipeline, notably obesity,” Trung Huynh, an analyst with RBC Capital Markets, said in a note to clients.
In its Q3 earnings call, Guegan said Pfizer will leverage “financial discipline” to combat patent losses and return the company to growth “towards the end of the decade.”
The full-year guidance Pfizer offers for 2027, which is typically disclosed at the end of the year, will provide the next high-profile public test of how Guegan translates the large pharma’s growth plans into a financial narrative.
